BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315
96537 results:

  • 1. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
    Ding W; Chen L; Xia J; Pei B; Song B; Li X
    Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Late port-site metastasis of unexpected gallbladder carcinoma after laparoscopic cholecystectomy: A case report.
    Aloraini A; Alshehri K; Alshammari R; Bin Onayq A; Ayesh M; Alzahrani M; AlShammari SA; Alsaif F
    Medicine (Baltimore); 2024 May; 103(18):e37880. PubMed ID: 38701302
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Video-Assisted vs Robotic-Assisted lung Lobectomies for Operating Room Resource Utilization and Patient Outcomes.
    Tupper HI; Lawson BL; Kipnis P; Patel AR; Ashiku SK; Roubinian NH; Myers LC; Liu VX; Velotta JB
    JAMA Netw Open; 2024 May; 7(5):e248881. PubMed ID: 38700865
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC.
    Lu Y; Langerman SS; McCain E; Magee K; Maund SL; Srivastava MK; Samant M
    JAMA Netw Open; 2024 May; 7(5):e249286. PubMed ID: 38700864
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.
    Lou J; Gong B; Li Y; Guo Y; Li L; Wang J; Liu W; You Z; Zhang H; Pan F; Liang B; Yang L; Zhou G
    Front Immunol; 2024; 15():1332303. PubMed ID: 38698843
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Structural Racism as a Contributor to lung cancer Incidence and Mortality Rates Among Black Populations in the United States.
    Robinson-Oghogho JN; Alcaraz KI; Thorpe RJ
    Cancer Control; 2024; 31():10732748241248363. PubMed ID: 38698674
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Radicality of mediastinal lymphadenectomy in minimally invasive pulmonary resection: a comparative analysis of uniportal and multiportal thoracoscopic approaches.
    Tulinský L; Kepičová M; Ihnát P; Mitták M; Adamica D; Čierna L; Martínek L
    Rozhl Chir; 2024; 103(2):48-56. PubMed ID: 38697813
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Association of log odds of positive lymph nodes with survival in patients with small cell lung cancer: Results from the SEER database.
    Gao T; Chang Y; Yue H
    Clinics (Sao Paulo); 2024; 79():100369. PubMed ID: 38696974
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. lung cancer-specific symptoms and fear of cancer recurrence among recurrence-free non-small cell lung cancer survivors.
    Lee G; Ahn A; Lee D; Kim TE; Kong S; Kang D; Kim HK; Shim YM; Cho J
    Support Care Cancer; 2024 May; 32(5):322. PubMed ID: 38695959
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis.
    Gong S; Li Q; Yu X; Yang S
    Front Immunol; 2024; 15():1362537. PubMed ID: 38694505
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.
    Takayama K; Kojima A; Honda C; Nakayama M; Kanemata S; Endo T; Muro K
    Cancer Med; 2024 May; 13(9):e7170. PubMed ID: 38693813
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
    Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
    Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
    Ferencz B; Török K; Pipek O; Fillinger J; Csende K; Lantos A; Černeková R; Mitták M; Škarda J; Delongová P; Megyesfalvi E; Schelch K; Lang C; Solta A; Boettiger K; Brcic L; Lindenmann J; Rényi-Vámos F; Aigner C; Berta J; Megyesfalvi Z; Döme B
    Cancer Immunol Immunother; 2024 May; 73(6):114. PubMed ID: 38693435
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Interstitial lung Abnormalities.
    Beasley MB
    Surg Pathol Clin; 2024 Jun; 17(2):215-225. PubMed ID: 38692806
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Prognostic Implications of Small Cell lung cancer Transcriptional Subtyping for CNS Metastases.
    Tringale KR; Skakodub A; Egger J; Eichholz J; Yu Y; Gomez D; Rimner A; Li B; Yamada Y; Wilcox J; Moss N; Imber BS; Rekhtman N; Baine MK; Rudin CM; Pike LRG
    JCO Precis Oncol; 2024 Apr; 8():e2300470. PubMed ID: 38691815
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A retrospective clinical analysis of 11 cases of PEComa from different sites.
    Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
    World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Progression to Lymph Node Metastasis After Spontaneous Regression of Pulmonary Adenocarcinoma Following Biopsy.
    Kaira K; Imai H; Mouri A; Yamaguchi OU; Kagamu H
    In Vivo; 2024; 38(3):1498-1502. PubMed ID: 38688648
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A Comparative Analysis of Implant-sparing Plan
    Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
    In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Artificial Intelligence-suggested Predictive Model of Survival in Patients Treated With Stereotactic Radiotherapy for Early lung cancer.
    Borghetti P; Costantino G; Santoro V; Mataj E; Singh N; Vitali P; Greco D; Volpi G; Sepulcri M; Guida C; Tomasi C; Buglione M; Nardone V
    In Vivo; 2024; 38(3):1359-1366. PubMed ID: 38688600
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
    Wu N; Yang X; Zhai Y; Lu W
    J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4827.